| 5.89 0.04 (0.68%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.13 | 1-year : | 8.33 |
| Resists | First : | 6.11 | Second : | 7.13 |
| Pivot price | 5.43  |
|||
| Supports | First : | 4.94 |
Second : | 4.23 |
| MAs | MA(5) : | 5.72 |
MA(20) : | 5.37 |
| MA(100) : | 3.9 |
MA(250) : | 3.69 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 77  |
D(3) : | 79.2 |
| RSI | RSI(14): 65.3 |
|||
| 52-week | High : | 6.11 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TOI ] has closed below upper band by 8.4%. Bollinger Bands are 25.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.95 - 5.97 | 5.97 - 5.99 |
| Low: | 5.45 - 5.48 | 5.48 - 5.5 |
| Close: | 5.85 - 5.89 | 5.89 - 5.93 |
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
Fri, 10 Jul 2026
The Oncology Institute (TOI) Proxy filing Summary - Quartr
Fri, 10 Jul 2026
TOIIW SEC Filings - The Oncology Institute Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 09 Jul 2026
Oncology Institute (TOI) director receives 25,833 fully vested RSU shares - Stock Titan
Thu, 09 Jul 2026
BTIG Maintains The Oncology Institute(TOI.US) With Buy Rating, Raises Target Price to $9 - Moomoo
Tue, 07 Jul 2026
Enterprise value to revenue forward of The Oncology Institute, Inc. – NASDAQ:TOI - TradingView
Tue, 07 Jul 2026
The Oncology Institute Completes Strategic Refinancing with - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 100 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 46 (%) |
| Shares Short | 6,690 (K) |
| Shares Short P.Month | 6,520 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -8 % |
| Operating Margin | -4.5 % |
| Return on Assets (ttm) | -12.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 41.2 % |
| Gross Profit (p.s.) | 0.82 |
| Sales Per Share | 5.45 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -16.83 |
| PEG Ratio | 0 |
| Price to Book value | -36.82 |
| Price to Sales | 1.07 |
| Price to Cash Flow | -27.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|